Business ❯ Mergers and Acquisitions

Pharmaceutical Industry

Investment Biotechnology Competition Drug Development Genetic Testing Perrigo Co Cancer Treatment Obesity Drugs AI in Drug Development Recent Acquisitions Market Competition Regulatory Approval Genetic Research Vaccine Development Biotech Companies Retail Pharmacy Startup Companies Rare Diseases Drugs Cancer Treatments Corporate Acquisitions Eli Lilly Ophthalmology Orchard Therapeutics Acquisition Rare Disease Drugs Genomics

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

The cash offer centers on tovorafenib for pediatric low‑grade glioma to advance Servier’s precision oncology strategy.

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

Lilly Strikes Up to $1.12 Billion Pact With Seamless Therapeutics for Hearing‑Loss Gene Editing

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Regeneron to Acquire 23andMe for $256 Million Following Bankruptcy Auction